Policy + Advocacy: End-of-Session Report

CBSA leads Policy + Advocacy efforts to support a collaborative, pro-innovation environment for life sciences in Colorado. We work to advance state and federal policies that support the companies in our ecosystem and the patients they serve.

Each year, our Policy + Advocacy team publishes an end-of-session report to update our community on the legislation impacting life sciences, our actions, and the outcomes at the State Capitol. Because our advocacy work is critical to our life sciences community, the CBSA team includes a full-time leader focused on Policy + Advocacy. We also work with one of the state’s top lobbying firms, Colorado Legislative Strategies.

CBSA’s Policy + Advocacy leadership is an important benefit for our members and our life sciences community. We are proud of our dedicated, year-round lobbying team. This team collaborated with our coalition partners representing health innovation to oppose legislation damaging to our ecosystem. While we remain opposed to several bills that were signed by the Governor, we were able to mitigate some of onerous provisions in Senate Bill 175, the Prescription Drug Affordability Review Board.

As we look back on the session, we are grateful to our partners at the Office of Economic Development and International Trade (OEDIT) and our collaboration to restore funding to the Advanced Industries Accelerator Grant Program. It’s a critical source of non-dilutive funding for life sciences.

CBSA wants to recognize our board, our lobbying team, and our partners for their commitment to advancing our Policy + Advocacy goals. Most importantly, thank you to our sponsors and members. Your support of CBSA funds our work on behalf of Colorado’s life sciences community at the state and federal level.

Categories: CBSA News